RNAi services

Invitrogen and genOway have signed a co-marketing agreement around RNAi related services. Under the terms of the agreement, Invitrogen and genOway will combine Invitrogen's expertise in RNAi research technologies with genOway's portfolio of transgenesis technologies and RNAi in vivo experience to create a services platform offering RNAi vector design through the creation of RNAi transgenic rodent models.

An important part of the discovery research and development process involves in vivo studies, often performed in animal models. As RNAi technology has advanced, the need to validate RNAi knockdown in model systems has been regarded as the next step in the eventual development of therapeutics based on the technique.

RNAi has rapidly become one of the most widely used techniques in drug discovery research. Using RNAi technology, scientists can turn genes 'off', enabling them to observe a cell's behaviour in the absence of the targeted gene's protein product. This may lead to better understanding of disease mechanisms and eventually, better therapies.